BY JOAKIM LUNDGREN TRYK
-
Emergency drug returned by Novo Nordisk: Zealand Pharma now wants to sell it on
Novo Nordisk has actually returned the Zegalogue emergency situation pen to Zealand Pharma after holding the civil liberties because 2022.
-
Zealand Pharma expects new research center in Boston commisioned by summer
The proving ground intends to increase the biotech business’s medicine r & d.
-
Money earmarked for new Zealand Pharma partnerships – expects more deals signed soon
The coming duration will certainly see even more collaborations for the Danish biotech business and a concentrated initiative on automation and AI.
-
Advisor: Novo Nordisk drops gender equality goals to satisfy MAGA USA
Political environment in the United States is thought to be the factor behind Novo Nordisk’s brand-new phrasing.
-
US lawyer expects Novo Nordisk’s patent lawsuit against Hims & Hers to drag on
The instance versus the United States compounders might end up being an examination of a lawful grey location in the swiftly expanding weight reduction market.
-
Novo Nordisk fails to hit all diversity targets for 2025
In 2021, Novo Nordisk established a number of targets to make sure sex equilibrium in the firm by the end of 2025. At the end of the year, the firm delayed a little behind on a num…
-
Best Thunderbolt docks: Extend your laptop’s capabilities
A Thunderbolt laptop computer docking terminal takes your workdesk to the following degree, with assistance for old and brand-new peripherals alike. It’s a need for an office…
-
Google Marketing Live 2025: Everything you need to know
Below is the wrap-up of Google’s occasion with AI updates concerning linking previously with consumers, producing vibrant web content and establishing a fellow marketing prof…
-
China Consumer Price Index (YoY) meets forecasts (-0.1%) in April
China Customer Rate Index (YoY) satisfies projections (-0.1%) in April …Read More
-
Gold Price Forecast: XAU/USD holds positive ground above $3,100, all eyes on US NFP data
Gold rate (XAU/USD) recuperates some shed ground to near $3,115 throughout the late American session on Thursday after dealing with some profit-taking in the previous session ̷…